Background/Objectives: The prognosis of acute lymphoblastic leukemia has significantly improved with the incorporation of innovative therapies such as immunotherapy, tyrosine kinase inhibitors, and CAR-T cell-based treatments. Drug resistance, mediated by genes such as ABCB1, has been associated with reduced treatment efficacy in various clinical scenarios. Although measurable residual disease (MRD) is the most reliable tool for monitoring treatment response in acute lymphoblastic leukemia, the relationship between ABCB1 expression and MRD remains unclear. Aims: To evaluate the expression of the ABCB1 resistance gene and explore its potential relationship with measurable residual disease. Methods: Prospective cohort where 57 patients with de novo diagnosis of acute lymphoblastic leukemia were admitted to the Hospital General de México “Dr. Eduardo Liceaga” between 2022 and 2024. Results: A total of 57 patients undergoing chemotherapy-based treatment were included, with a majority being male (n = 30, 52.6%) and a mean age of 32 years (range 18–71 years). Analysis of ABCB1 gene expression revealed that 35.1% (n = 20) had low expression, 40.4% (n = 23) had overexpression, and 24.6% (n = 14) showed absent expression. No statistically significant association was identified between MRD positivity and the presence of the Philadelphia chromosome (p = 0.171, 95% CI) or the ABCB1 high-risk group (high or absent expression) (p = 0.538, 95% CI). Conclusions: Although ABCB1 expression remains a valuable tool for understanding drug resistance in acute lymphoblastic leukemia, this study did not identify a significant relationship with MRD. MRD continues to be the most reliable prognostic factor in chemotherapy-based treatments for acute lymphoblastic leukemia, underscoring its importance in personalized medicine.
Background/Objectives: Adult acute lymphoblastic leukemia (ALL) often has poor outcomes, especially after relapse or treatment failure. Many patients eventually become ineligible for curative treatment and require only supportive care or low-intensity chemotherapy. However, data on prognosis and predictive factors in this context are limited. The study aim was to evaluate survival and identify prognostic factors in patients with relapsed/refractory ALL receiving supportive care. Methods: We conducted a retrospective observational study of 59 patients at two tertiary hospitals in Mexico. All patients had exhausted curative treatment options. Clinical variables at diagnosis and relapse were analyzed, including age, leukocyte counts, relapse timing, prior treatment lines, transfusion needs, and use of prognostic scores. Kaplan–Meier analysis was used to estimate survival, and multivariate models were applied to identify predictors of overall survival. Results: Fifty-nine patients were included (median age 31 years, balanced gender). Most received two prior high-intensity chemotherapy lines. Median overall survival was 137 days, with transfusion requirements being the only significant prognostic factor; neither the Palliative Prognostic Index nor the Charlson Comorbidity Index demonstrated predictive value. Conclusions: In patients with relapsed/refractory ALL managed with supportive care, survival remains limited. Transfusion dependence is a strong adverse prognostic factor, likely reflecting disease burden and logistical barriers to outpatient care. These findings highlight the need for earlier integration of palliative care and the development of tailored prognostic tools for this population.
La leucemia linfoblástica aguda es un tipo de cáncer común en niños y adultos jóvenes, y su tratamiento implica el uso de quimioterapia y otros medicamentos. Sin embargo, a pesar de las altas tasas de remisión inicial, muchas personas experimentan recaídas y la supervivencia a largo plazo es baja. Este estudio buscó sintetizar los tratamientos utilizados en casos de leucemia linfoblástica aguda recurrente y su aplicación alrededor del mundo. Se realizó una revisión exhaustiva de estudios retrospectivos y prospectivos publicados entre 2012 y 2022 en bases de datos médicas. Los tratamientos más comunes para la leucemia linfoblástica aguda recurrente incluyen combinaciones de quimioterapia, como la terapia con fludarabina, citarabina y mitoxantrona. También se han utilizado esquemas de inducción más intensivos, como el HyperCVAD. Sin embargo, hay poca experiencia con otros medicamentos, como inhibidores del proteosoma y agentes hipometilantes.
Purpose: Despite advances in the treatment of adult acute lymphoblastic leukemia (ALL), relapse remains the most significant challenge in improving prognosis. Measurable residual disease (MRD) assessment can predict bone marrow relapse based on MRD positivity. As access to innovative therapies remains limited because of the high cost, chemotherapy is the widely utilized treatment option. The efficacy of a combination of bortezomib and Hyper-CVAD has been reported in patients with multiple myeloma; however, its efficacy has not yet been confirmed in patients with ALL. Methods: This prospective cohort study involved patients with ALL who presented with MRD-positive results or relapse and received treatment with a combination of bortezomib and Hyper-CVAD at two reference centers in Mexico City. Results: Of the 20 patients with positive MRD included in this study, 60% (n = 12) exhibited MRD negative results after combination treatment, 30% (n = 6) persisted positive MRD results, and 10% (n = 2) passed away. Of the 23 patients with bone marrow relapse, 43.5% (n = 10) achieved a second complete remission (2CR), 34.8% (n = 6) exhibited refractory status, and 21.7% (n = 5) passed away. To achieve a 2CR, 20% (n = 2) patients required less than four cycles of treatment, 50% (n = 5) required four cycles (two A and B cycles each), and 30% (n = 3) required six cycles. Conclusion: The combination of bortezomib and Hyper-CVAD treatment exhibited better results in achieving MRD negative results, indicating its potential as a promising first-line treatment strategy for ALL.
29 June 2023 in Revista Colombiana de Cancerología
Introducción. La invasión o infiltración al sistema nervioso central (SNC) puede presentarse tanto en el diagnóstico como en el seguimiento. Factores como la hiperleucocitosis, fenotipo T, t (1;19) o punciones traumáticas aumentan el riesgo. Los resultados con tratamiento intratecal son variables y requieren la combinación de quimioterapia sistémica o radioterapia. La asociación con infiltración de la médula ósea empeora el pronóstico. Objetivos. En este estudio se describen las características de los casos con leucemia linfoblástica aguda (LLA) e infiltración del SNC en pacientes atendidos en dos centros de referencia en México. Métodos. Estudio observacional, descriptivo, retrospectivo, en pacientes adultos con LLA e infiltración del SNC en el diagnóstico o durante el seguimiento, detectada por citomorfología o por citometría de flujo. Resultados. Se estudiaron 30 pacientes, 73,3 % fueron hombres, la media de edad fue 29 años (17 a 57 años). El 86,7 % (n=26) correspondieron a pacientes con un riesgo alto de recaída y mayormente con fenotipo B (93,3 %). En el 70,0 % de los casos el diagnóstico se realizó por citomorfología y en el 26,7 %, por citometría de flujo; el síntoma principal fue cefalea (56,7 %) y el 10,0 % cursaron con alguna neuropatía periférica. El tiempo promedio para recaída fue de 417 días, el 66,7 % (n=20) logró una respuesta favorable a quimioterapia intratecal intensiva dos veces por semana. Un 33,3 % (n=10) ameritó la combinación con otras estrategias. La infiltración del SNC en un periodo menor de 400 días se asoció con un peor pronóstico. Conclusión. La infiltración al SNC es una complicación esperada que requiere una rápida resolución para prevenir la recaída en la médula ósea.